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Purpose: In this prospective study we analyzed the immediate and midterm outcome in patients with abdominal aorta
infection (mycotic aneurysm, prosthetic graft infection) managed by excision of the aneurysm or the infected vascular
prosthesis and in situ replacement with a silver-coated polyester prosthesis.
Methods: From January 2000 to December 2001, 27 consecutive patients (25 men, 2 women; mean age, 69 years) with an
abdominal aortic infection were entered in the study at seven participating centers. Infection was managed with either
total (n  18) or partial (n  6) excision of the infected aorta and in situ reconstruction with an InterGard Silver (IGS)
collagen and silver acetate–coated polyester graft. Assessment of outcome was based on survival, limb salvage, persistent
or recurrent infection, and prosthetic graft patency.
Results: Twenty-four patients had prosthetic graft infections, graft–duodenal fistula in 12 and graft-colonic fistula in 1;
and the remaining 3 patients had primary aortic infections. Most organisms cultured were of low virulence. The IGS
prosthesis was placed emergently in 11 patients (41%). Mean follow-up was 16.5 months (range, 3-30 months).
Perioperative mortality was 15%; all four patients who died had a prosthetic graft infection. Actuarial survival at 24
months was 85%. No major amputations were noted in this series. Recurrent infection developed in only one patient
(3.7%). Postoperative antibiotic therapy did not exceed 3 months, except in one patient. No incidence of prosthetic graft
thrombosis was noted during follow-up.
Conclusion: Preliminary results in this small series demonstrate favorable outcome with IGS grafts used to treat infection
in abdominal aortic grafts and aneurysms caused by organisms with low virulence. Larger series and longer follow-up will
be required to compare the role of IGS grafts with other treatment options in infected fields. (J Vasc Surg 2003;38:
983-9.)
Infection of an aortic prosthetic graft is one of the
complications most dreaded by vascular surgeons. Al-
though estimated at between 0.5% and 1%,1,2 the true
incidence is certainly higher3 because of patients lost to
follow-up, insufficient follow-up, or lack of information
about late infections. Conventional management of aortic
prosthetic graft infections consists of excision of the in-
fected graft, ligation of the infrarenal aorta, and extra-
anatomic bypass grafting.4 Currently available alternative
treatment options to this traditional approach include in
situ replacement of the infected prosthesis with an arterial
allograft5 or autogenous vein graft,6 and reconstruction
with an antibiotic-impregnated prosthetic graft.7 The long-
recognized efficacy of silver on microbial agents and the
efficacy of silver used as an antimicrobial agent on medical
devices8-11 led us to use the InterGard Silver prosthesis
(IGS; InterVascular, La Ciotat, France) for management of
infected aortic prostheses. Manufactured of knit or woven
polyester, the IGS prosthetic graft is coated with type I
bovine collagen and silver acetate. Silver acetate inhibits
colonization of the prosthesis and contiguous tissues by
microorganisms during the postoperative period. The re-
sults of in vitro and in vivo animal studies have demon-
strated the absence of local or systemic toxicity of the IGS
prosthesis and its antimicrobial efficacy; 25% of the silver
salts remained on the prosthesis 20 days after implanta-
tion.12,13 The IGS prosthesis is not approved for use in the
United States. We analyzed immediate and midterm results
achieved with the IGS prosthesis for in situ replacement to
treat aortic infections (infected aortic prosthetic graft, my-
cotic aneurysm).
MATERIAL AND METHODS
From January 2000 to December 2001, a nonrandom-
ized prospective study was conducted in seven centers that
used the IGS prosthesis for in situ replacement of infected
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aortic grafts.* In these seven centers all patients with aortic
infection received the IGS prosthesis, to test its efficacy in
treatment of aortic infection. Diagnosis was based on find-
ings at clinical examination and computed tomography
(CT). When possible, specimens for microbiologic culture
were obtained before surgery, and appropriate antibiotic
therapy was prescribed. In the remaining patients, broad-
spectrum antibiotic therapy, especially vancomycin against
Staphylococcus, was administered before and during the
operation. Preoperative arteriography was performed when
possible.
There was no uniform treatment protocol; rather, this
was left to the discretion of each surgeon.
Surgery was performed with a vertical midline trans-
peritoneal incision in all patients but one, in whom a
retroperitoneal incision was used to approach a mycotic
aneurysm.
Total graft excision was performed when the infection
involved the entire prosthesis; partial excision was per-
formed when infection was limited to the body or a single
limb of the prosthesis and when the remainder of the
prosthesis was well-encapsulated. The prosthetic graft was
covered with a pedicled anterior omentoplasty when possi-
ble. During surgery, specimens were taken for bacteriologic
analysis, and the excised prosthetic graft was placed in
culture medium. Povidone-iodine standard solution was
used for irrigation of the infected fields after debridement
of surrounding tissues. Serial CT scans of the IGS prosthe-
sis were obtained before discharge from the hospital, 3 and
6 months after surgery, then every 6 months. For analysis,
patient data were updated to June 2002.
The primary end points of the study were patency of the
IGS prosthetic graft, limb salvage, and patient survival
(determined with the Kaplan-Meier method).
RESULTS
From January 2000 to December 2001, the seven
participating centers entered 27 patients (25 men, 2
women) with mean age 69 years (range, 44-87 years) in this
study (Table I). Eighty-seven percent of patients were
present or past cigarette smokers, with a mean of 53  27
pack-years. Other pertinent risk factors included coronary
artery disease (36%), hypertension (41%), type II diabetes
mellitus (14%), hyperlipidemia (18%), chronic obstructive
pulmonary disease (22%), and renal failure (creatinine con-
centration, 3.0 mg/dL; 9%).
Three patients had mycotic aneurysms (two aortic an-
eurysms, one common iliac artery aneurysm). Clinical find-
ings at presentation are shown in Table II. CT scans re-
vealed chronic rupture of the aneurysm in all three patients.
Infection was secondary to hematogenous spread of a den-
tal infection, complication of subacute bacterial endocardi-
tis, and infection of a kidney transplant, respectively. All
three mycotic aneurysms were treated emergently with
complete excision, debridement of surrounding tissues,
and in situ reconstruction with an IGS prosthesis covered
with a pedicled omentoplasty. Bacteriologic cultures were
positive in two patients (Table III). No in-hospital death
*The number of aortic infections (mycotic aneurysm, infected prothetic
graft) managed with an IGS prosthesis by each author and at each
participating center was as follows: M. Batt, Nice, France (n  11); J. L.
Magne, Grenoble, France (n  5); P. Alric, Montpellier, France (n  4);
A. Muzj and C. Ruotolo, Naples, Italy (n  4); K. J. Ljungstrom,
Karlinska-Danderyd, Sweden (n 1); R. Garcia-Casas, Pontevedra, Spain
(n  1); M. M. Simms, Birmingham, England (n  1).
Table I. Aortic infections in 27 study patients
Type of aortic infection
Mycotic aneurysm
(n  3)
Graft infection
with fistulas
(n  13)
Graft infection
without fistulas
(n  11)
Total
(N  27)
n % n % n % n %
Presentation
Emergent 3 100 7 54 1 9 11 41
Planned 0 6 46 10 91 16 59
Graft removal
Total 3 100 12 92 6 56 21 78
Partial 0 1 8 5 44 6 22
Repeat operation
Early 0 3* 23 1 9 4 15
Late 1‡ 33 0 3§ 27 4 15
Death
Operative 0 3 23 1 9 4 14.8
Late 0 0 0
Graft patency 100 100 100 100
Recurrent infection 0 0 1 9 1 3.7
*Duodenal leakage, 2; femoropopliteal bypass, 1.
†Postoperative intestinal occlusion.
‡Access for hemodialysis.
§Femoropopliteal bypass, 2; sigmoidectomy, 1.
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occurred, and the three patients were followed up for a
mean of 16 months (range, 3-26 months). None of the
patients died during follow-up, with Kaplan-Meier survival
of 100% at 2 years. No follow-up CT scans demonstrated
any recurrent infection or perigraft fluid collection. Patients
received antibiotic therapy for no more than 3 months,
except for the one patient operated on to treat a mycotic
aneurysm after subacute bacterial endocarditis, who re-
ceived antibiotic therapy for 6 months. Primary and sec-
ondary patency of the bypass grafts at 24 months was 100%.
In 24 of the 27 patients, the aortic prosthetic graft was
infected. Twelve of these 24 patients had a secondary
graft-duodenal fistula (8 graft duodenal erosions, 4 direct
aortoduodenal fistulas due to communication at the level of
a proximal false aneurysm), and 1 patient had a graft-
sigmoid fistula. The remaining 11 patients had prosthetic
graft infection without intestinal or duodenal involvement
(Table I).
Initial graft placement was prompted by occlusive dis-
ease in 17 patients (70%) and by an aneurysm in 7 patients
(30%). Mean interval between placement of the prosthetic
graft and diagnosis of graft infection was 78 months (range,
1-264 months). The bypass configuration of the infected
grafts was aortoaortic in 2 patients, aortobiiliac in 7 pa-
tients, aortobifemoral in 13 patients, and aortounifemoral
in 2 patients. All of the 24 infected prosthetic grafts were
made of polyester. Clinical findings at presentation are
shown in Table II. CT scans revealed perigraft fluid collec-
tion in 14 patients, with an air-fluid interface in 7 patients,
retroperitoneal abscess in 10 patients, ureterohydrone-
phrosis in 4 patients, and proximal anastomotic false aneu-
rysm in 4 patients.
Aortic reconstruction with the IGS prosthesis was per-
formed as an emergency procedure in 8 patients (33%),
because of gastrointestinal bleeding with shock (n  6),
acute lower limb ischemia (n  1), and peritonitis from a
sigmoid fistula (n  1); the remaining 16 patients (66%)
underwent elective repair.
In 6 of 24 patients with an infected aortic prosthesis,
the infection was limited to a segment of the graft (body of
the prosthesis in 1 patient, limb in 5 patients); the remain-
der of the prosthesis was well-encapsulated. In all patients
but one, the infected graft limb or body was replaced in situ
with a segment of IGS prosthesis and covered with a
pedicled omentoplasty.
Eighteen of 24 patients had complete prosthetic graft
infection. Ten had a retroperitoneal abscess. All 18 of these
patients underwent complete excision of the prosthesis,
debridement of surrounding tissues, and in situ replace-
ment with an IGS prosthesis (aortoiliac in 2 patients, aor-
tobiiliac in 3 patients, aortobifemoral in 11 patients, and
aortounifemoral in 2 patients, with conservation of the
encapsulated, infection-free crossover bypass in 1 of these
last 2 patients; Table IV). In 16 of these 18 patients, the
IGS prosthesis was covered with a pedicled omentoplasty.
For the 12 patients with a prosthetic graft–duodenal
fistula, duodenorrhaphy was performed, with two layers of
suture material (n  10) or segmental duodenal resection
and end-to-end suture in two layers, because of severe loss
of duodenal substance (n  2). A gastroduodenal catheter
was placed in the proximal duodenum. Six of these patients
required an associated jejunostomy. Two patients with a
prosthetic graft–duodenal fistula underwent early repeat
operation (days 7 and 15, respectively), because of duode-
nal leakage after duodenorrhaphy closed solely with sutur-
ing. The two recurrent duodenal fistulas were not due to
Table II. Clinical symptoms in 24 patients with infected
aortic prosthetic graft
Symptoms n %
Mycotic aneurysm (n  3)
Sepsis (fever, hyperleukocytosis, septicemia) 3 100
Abdominal pain 3 100
Infected prosthetic grafts (n  24)
Sepsis (fever, hyperleukocytosis, septicemia) 9 37.5
Severe gastrointestinal bleeding; collapse 6 25
Abdominal pain 4 17
Inguinal abscess 8 33
Acute lower limb ischemia 1 4
Aortic false aneurysm 2 8
Anorexia and weight loss 2 8
Table III. Bacteria isolated in positive bacteriologic
cultures of infected prostheses and mycotic aneurysms
Organism n %
Mycotic aneurysms (n  2)
Streptococcus 2 66
Enterobacteriaceae 1 33
Haemophilus parainfluenzae 1 33
Candida albicans 1 33
Infected prosthetic grafts (n  22)
Staphylococcus epidermis 5 24
Staphylococcus aureus 5* 24
Streptococcus 5 24
Escherichia coli 4 19
Enterococcus faecalis 7 33
Bacteroides fragilis 2 10
Clostridium perfringens 2 10
Proteus mirabilis 1 5
Klebsiella 1 5
C albicans 4 19
Corynebacterium 1 5
*Methicillan-resistant S aureus, 2.
Table IV. Type of arterial reconstruction in 27 patients
with InterGard Silver* prosthetic graft
n %
Aortoaortic tube graft 4 (1 mycotic aneurysm) 15
Aortobiiliac bypass graft 4 (1 mycotic aneurysm) 15
Aortobifemoral bypass graft 11 41
Aortounifemoral bypass graft 2 7
Iliofemoral graft 6 (1 mycotic iliac aneurysm) 22
*InterVascular, La Ciotat, France.
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recurrent graft infection but to breakdown of the duodenal
wall, which was of poor quality. One of these patients died
after the repeated surgery (day 50); he was 80 years old and
in poor physiologic condition. The other patient under-
went duodenal resection with Y-shaped jejunal anastomo-
sis, with no recurrent infection of the IGS prosthesis and an
uneventful recovery.
Bacteriologic cultures were negative in 2 patients (8%).
In the 22 patients with positive cultures (92%), several
organisms were cultured from the excised graft in 16; only
one organism was cultured in the other 6 patients (Table
III). In nearly all cases, these were organisms with low
virulence.
Perioperative mortality rate was 16.6% (4 of 24 pa-
tients). Three patients who died had undergone complete
prosthetic graft replacement, and 1 patient died after seg-
mental replacement of the body of the prosthesis. Periop-
erative mortality rate was 23% (3 of 13 patients) for patients
with an enteric fistula, versus 9% (1 of 11 patients) for
patients with an infected aortic prosthetic graft without an
enteric fistula.
In 2 of the 24 patients entered in the study after
infection of the initial prosthetic graft, infection developed
in the early postoperative period. The first early infection
was revealed 2 weeks postoperatively by acute ischemia of a
lower limb after occlusion of a prosthetic graft limb. Ex-
ploratory surgery revealed a retroperitoneal abscess. Bacte-
riologic cultures yielded methicillin-resistant Staphylococcus
aureus (MRSA). The second early graft infection was re-
vealed 10 weeks postoperatively by the finding of septice-
mia. Bacteriologic analysis revealed the presence of Bacte-
roides fragilis. Both patients had an uneventful course after
in situ replacement with an IGS prosthesis.
Among the 22 patients with late infection after place-
ment of the initial prosthetic graft, none died who under-
went planned replacement of the infected prosthetic graft.
In contrast, four of eight patients who underwent emer-
gency repair died in-hospital (mortality, 50%), respectively,
4, 6, 45, and 50 days postoperatively. None of these deaths
was related to sepsis. One of two early deaths was due to
multiple organ failure in a 87-year-old man with a ruptured
proximal aortic false aneurysm; the other early death was
secondary to cardiac and respiratory failure in a 57-year-old
patient with coronary disease and cardiac insufficiency
(ASA III) who had a prosthetic graft–duodenal fistula. The
third postoperative death, which occurred on day 45, was
due to colonic ischemia in an 87-year-old patient with
cachexia; autopsy demonstrated no recurrent infection of
the IGS prosthesis. The fourth postoperative death oc-
curred after 50 days; a recurrent fistula at the level of the
duodenal suture had been found at repeat surgery (day 15).
No prosthetic graft thrombosis or amputation was ob-
served in any of the 24 patients.
None of the 20 patients who survived the hospital
course was lost to follow-up (mean follow-up, 17 months;
range, 1-31 months). The probability of survival at 24
months was 85%  7%. All patients received antibiotic
therapy postoperatively for a mean duration of 2 months
(range, 3 weeks–3 months). There was no incidence of IGS
thrombosis. Primary and secondary patency of the bypass
grafts at 24 months was 100%.
In one patient (3.7%) who had undergone segmental
replacement of a graft limb without omentoplasty, recur-
rent infection developed, with cutaneous fistulization, in
the sixth postoperative month. The associated perigraft
fluid collection was drained, but bacteriologic cultures were
negative, and there was no recurrence. The other 19 survi-
vors underwent CT verification of IGS prosthesis status.
No CT scans demonstrated recurrent infection or perigraft
fluid collection.
DISCUSSION
Immediate and midterm results in our study patients
reveal the safety and efficacy of the IGS prosthesis for
management of mycotic aneurysm and aortic prosthetic
graft infection, two of the most serious complications seen
by vascular surgeons. The early mortality rate was 15%, and
none of the deaths was related to recurrent infection.
Outcome after recurrent infection (3.7%) was favorable.
Because the IGS prosthetic graft was used in situations in
which risk for infection is usually high (10 retroperitoneal
abscesses, 12 graft-duodenal fistulas, 1 colonic fistula), and
often in an emergency setting because of a life-threatening
situation (41%), the results of our series compare favorably
with those in the literature (Table V).
Traditional management of infected aortic prosthetic
grafts, consisting of extra-anatomic bypass grafting, has
several disadvantages compared with in situ replacement.
First, the procedure is longer and patency at midterm is not
so good. No instance of graft thrombosis and no amputa-
tions occurred in our series, even though 70% of the
patients had severe atherosclerotic lesions; these results are
comparable to those reported for various methods of in situ
aortic replacement (Table V). Second, aortic stump suture
is not always possible when the stump is short; the risk for
thrombosis ascending toward the renal arteries is com-
pounded by the risk for aortic stump blowout.4,14 No
anastomotic rupture occurred in our series with the IGS
prosthesis. Third, blood supply to the pelvis and the left
colon is usually compromised with conventional treatment,
because it is impossible to revascularize the internal iliac
arteries or the inferior mesenteric artery. Bacourt et al14
reported five patients with colonic ischemia and two pa-
tients with paraplegia in their series.
One theoretical advantage of extraanatomic bypass
grafting is lower risk for graft infection, because revascular-
ization is usually performed at a distance from the site of
infection. However, secondary infections have been noted
in as many as 27% of recent series (Table V). Recurrent
infection developed in only one patient (3.7%) in our series,
with mean follow-up of 16.5 months. While 13 of our
patients had relatively low-grade infection (negative cul-
tures, n  3; Staphylococcus epidermidis, n  5; Candida,
n  4; Corynebacterium, n  1), 44% had signs of sepsis,
with S aureus (MRSA, n  2), Enterococcus faecalis, and
Streptococcus organisms most frequently isolated. The same
JOURNAL OF VASCULAR SURGERY
November 2003986 Batt et al
distribution was reported by Zegelman and Gunther,15
who found S epidermis in 6 patients, Pseudomonas in 11
patients, and S aureus in 47 patients in their series. In our
series, the infected prosthesis was surrounded by purulent
material in 10 patients, and 13 patients had an enteric
fistula; even in these conditions, the IGS prosthesis resisted
infection, and no anastomotic rupture occurred. Thorough
debridement of all infected surrounding tissues is essential
and must be completed with irrigation with povidone-
iodine solution; the prosthetic graft should also be covered
with a pedicled omentoplasty when possible.16
Traditional management of partially infected prosthetic
grafts consists of complete excision. However, Miller17
demonstrated that when the remainder of the prosthesis is
well-encapsulated, it can be safely left in place. For patients
with poor general condition, this reduces operative mor-
bidity and mortality; the new prosthesis is placed in situ in
an adjacent position. The apparently better outcome with
partial graft removal may not result from the technique but
because the infection was limited. Six patients with segmen-
tal graft infection underwent in situ replacement of a seg-
ment of IGS prosthesis. This approach was used for patients
in poor general condition in whom the remainder of the
prosthesis was macroscopically free of infection. In one of
these six patients, recurrent infection developed, with a
favorable outcome; another patient died after recurrence of
a duodenal fistula. In contrast, 3 deaths occurred among 18
patients who required complete replacement of an infected
prosthetic graft.
Thirteen aortic graft infections in our series were due to
graft-duodenal fistula (n 12) or graft-sigmoid fistula (n
1). Three of these 13 patients (23%) died. One death was
due to recurrence of the sutured duodenal fistula. If the
Table VI. Results of management of digestive fistulas
with extranatomic bypass grafting (conventional) and
in situ graft replacement
Author
Operative mortality
(%)
Conventional treatment
O’Hara et al19 51
Bacourt et al14 30
Yeager et al4 19
Bandyk et al18 29
In situ graft replacement
Allograft
Ruotolo et al41 38
Verhelst et al23 29
Leseche et al21 30
Vogt et al22 14
Noel et al16 50
Autogenous vein
Nevelsteen et al25 50
Antibiotic-bonded prosthesis
Hayes et al26 25
IGS*
Current series 23
*Intergard silver; InterVascular, La Ciotat, France.
Table V. Results of management of aortic prosthetic graft infection with extraanatomic bypass grafting (conventional)
and in situ graft replacement
Author Year
No. of
patients
Mean
follow-up
(mo)
Operative
mortality
(%)
Amputation
(%)
Secondary
infection
(%)
Conventional treatment
O’Hara et al19 1986 54 13 28 27 27
Bacourt et al14 1992 98 34.6 24 16 7
Sharp et al20 1994 20 — 3.7 5 5
Yeager et al4 1999 60 41 13 10 10
Bandyk et al18 2001 31 26 21 9 3
In situ graft replacement
Allograft
Kieffer et al5 1993 43 13.8 12 0 7
Verhelst et al23 2000 90 36 17 1 1
Leseche et al21 2001 28 35.4 17.8 0 0
Vogt et al22 2002 49 27 6 0 2
Noel et al16 2002 56 5.3 13 5 4
Autogenous vein
Nevelsteen et al25 1995 15 17 7 7 0
Clagett et al24 1997 41 32 7.3 5 0
Bandyk et al18 2001 10 26 10 10 3
Antibiotic bonded prosthesis
Hayes et al26 1999 11 — 18 0 9
Young et al27 1999 9 36 8 0 11
Bandyk et al18 2001 16 18 0 0 10
IGS* prosthesis
Zegelman & Gunther15 2002 44 11 6.5 — 6.5
Current series 2003 27 17 16.6 0 3.7
*Intergard silver; InterVascular, La Ciotat, France.
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opening of the duodenal fistula is fairly small and the
duodenal wall is of good quality, suturing alone and place-
ment of a gastroduodenal catheter in proximal duodenum
may suffice. When the duodenal wall is of poor quality or
the opening is large, prevention of fistula recurrence re-
quires resection of the fourth duodenum and the proximal
jejunum, and lateral anastomosis or Y-shaped anastomosis
to the second duodenum. The early mortality rate in this
series is within the range reported in recent series with
alternative therapies (Table VI). None of the three deaths
was due to recurrent graft infection.
Recent publications5-16,18-29 have reported the safety
of in situ replacement of infected aortic prosthetic grafts or
mycotic aneurysms of the infrarenal aorta using various
graft materials (Table V).
In situ replacement with cryopreserved arterial allograft
is another option for treatment of these infected grafts. In
experimental studies, allografts were more resistant to in-
fection than conventional prostheses were,30-32 although a
report from the Mayo Clinic16 found that 23% of compli-
cations were attributable to the allograft, including hemor-
rhage, persistent infection, occlusion, and pseudoaneu-
rysm. Autogenous reconstruction with the superficial
femoral veins is the most effective means to prevent second-
ary infection, but the additional operative time required is
not always compatible with life-threatening situations or
fragile patients.18 Previous deep venous thrombosis is a
contraindication to this operative approach. Similarly, a
history of femoropopliteal reconstruction complicates exci-
sion of a segment of the superficial femoral vein.25 Postop-
erative compartment syndrome has also been described in
12% of patients.24
The efficacy of rifampicin-impregnated polyester pros-
theses for in situ replacement of infected aortic prosthetic
grafts has been demonstrated both experimentally33,34 and
in clinical trials.18,26,27 However, their efficacy depends on
the bacterium responsible for the infection. Experimental
studies have shown that gelatin-coated polyester prostheses
impregnated with rifampicin exhibit satisfactory resistance
to S epidermis but are insufficient against MRSA and Esch-
erichia coli.35,36 These experimental findings confirm the
work of Hayes et al,26 who emphasized the limitations of
rifampicin-bonded polyester grafts for management of ma-
jor aortic graft infection with MSRA. This problem war-
rants particular attention because of the appearance of
rifampicin-resistant strains of S epidermis.37
The evolution of nosocomial infections in the United
States and in Europe highlights the changing epidemiology
of infections, because bacteria such as S aureus and S
epidermis are increasingly resistant to antibiotic therapy.38
Because of risk for bacterial resistance to rifampicin, alter-
natives to the antibiotic agents bonded to these prostheses
must be envisaged for in situ replacement of infected aortic
prosthetic grafts. Experimentally, bacterial resistance devel-
ops more rapidly and more easily with antibiotic agents
than with antiseptic agents.39 The antiseptic properties of
silver salts have long been recognized. Because of their
biocompatibility, and experimental and clinical efficacy
when used as antimicrobial agents on implantable medical
devices,8-11 we selected the IGS prosthesis for management
of infected aortic prosthetic grafts. Our study findings show
that in situ IGS prostheses are a safe and effective option for
management of mycotic aneurysms and infected aortic
prosthetic grafts.
This study does, however, have limitations. In particu-
lar, there were no instances of Pseudomonas graft infection
in this series, 13 patients had low-grade infection, and the
number of infected grafts treated at each participating
center varied considerably. However, prosthetic graft infec-
tions are infrequent, and few cases are treated. Mean fol-
low-up was only 16.5 months, which is insufficient for
detection of late infection, and prolonged follow-up of the
patients in this series will be necessary. Finally, a recent
experimental study40 reported that rifampicin-impregnated
prostheses are more resistant to infection than IGS prosthe-
ses are. Clinical trials do not confirm these experimental
findings, however, and secondary infections are more fre-
quent with rifampicin-impregnated prostheses than with
IGS prostheses (Table V). This discrepancy between exper-
imental findings and clinical trials is probably attributable
to the fact that S aureus and S epidermis develop resistance
to rifampicin more rapidly than to silver salts.26,36,38
In conclusion, preliminary results of this series show
favorable results with use of IGS graft for in situ replace-
ment of infected aortic prosthetic grafts and mycotic aneu-
rysms. The IGS graft may be an appropriate option for
treatment of infected aortic grafts, particularly when autog-
enous deep vein reconstruction is not possible. However,
this series has limitations in that most of the patients had
late graft infection caused by organisms with low virulence.
Furthermore, long-term follow-up will be necessary to
exclude recurrent graft infection. In addition, larger series
will be required to compare the role of IGS grafts in
infected fields with other available treatment options.
We thank Ms Nancy Rameau and Ms Marie-Louise
Torti for assistance in preparation of the manuscript.
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